Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Shares Outstanding (Weighted Average) (2020 - 2026)

TriSalus Life Sciences has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $51.5 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 80.67% year-over-year to $51.5 million; the TTM value through Mar 2026 reached $51.5 million, up 80.67%, while the annual FY2025 figure was $37.9 million, 418.35% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $51.5 million at TriSalus Life Sciences, up from $7.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $51.5 million in Q1 2026 and troughed at $299936.0 in Q3 2022.
  • A 5-year average of $14.2 million and a median of $7.4 million in 2025 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 92.86% in 2023 and later surged 5256.12% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $15.8 million in 2022, then tumbled by 47.65% to $8.3 million in 2023, then decreased by 11.72% to $7.3 million in 2024, then grew by 1.25% to $7.4 million in 2025, then surged by 596.24% to $51.5 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TLSI at $51.5 million in Q1 2026, $7.4 million in Q4 2025, and $7.4 million in Q3 2025.